TIAP - Toronto Innovation Acceleration Partners’ Post

🌴💸 A tropical-themed Financial Friday update for you and I can only apologise for my terrible taste in clothing, luckily the positive investment rounds this week should distract you from that (alternatively just listen to the audio!) A comprehensive overview is in my video but a brief rundown of the funding this week is below: 💰 Zenas BioPharma - $200 million series C 💵 Bluejay Therapeutics - $182 million series C 🤑 Attovia Therapeutics - $105 million series B 💲 Aardvark Therapeutics - $85 million series C 💳 Latus Bio - $54 million launch #financialfriday #biotechinvestment #vcfunding

🚨 Exciting updates from The BioHub! 🚨 Next week, we have an EXCLUSIVE episode featuring Spur Therapeutics. We'll dive into their rebrand from Freeline and their acquisition of SwanBio Therapeutics. Thankyou Michael Parini for joining us! 🎙️ Don't miss out! Episode drops next Wednesday. Stay tuned! #BioHubPodcast #Biotech #Pharma #Innovation #Podcast

🔥 The BioHub's First Ever Exclusive! 🔥 Big news from Freeline Therapeutics! They've rebranded as Spur Therapeutics and just acquired SwanBio Therapeutics! 🌟 What a huge week! Next week, we've got no other than the CEO of Spur, Michael Parini, joining us to discuss these game-changing developments! This is an episode you absolutely cannot miss. Stay tuned! 🎧 #BioHubPodcast #Exclusive #GeneTherapy #SpurTherapeutics #Innovation #MichaelParini #AvetixGroup

Golden Seeds is excited to welcome Divya Yerraguntla, Head of Go-To-Market at Treehill Partners for an engaging conversation with Golden Seeds member Maya Das, centered on the opportunities and challenges for angel investors in the early-stage therapeutics space.   During tomorrow's Trend Talk, Divya will share insights into what it takes to successfully bring early-stage drugs to market and the critical factors angel investors should consider in this evolving ecosystem. #angelinvesting #therapeutics #investing

Check out Optimum's latest podcast featuring an expert panel discussing the issue of diversity in clinical trial recruitment. Thanks to Germo Gericke, Annalisa Jenkins and John Maher for taking part!

Listen to Optimum Strategic Communications latest podcast around #clinicaltrials

Qatar Investment Authority (QIA) dedicated to healthtech by investing in innovative healthcare companies as well as funds Latest investment in startups: 🇺🇸 Outpace Bio (Aug 2024, Series B, $144 million, CEO Marc Lajoie) is a cell therapy company using unrivaled AI-powered protein design to program immune cells for improved function inside patients battling solid tumors 🇺🇸 Iambic Therapeutics (Jun 2024, Series B , $50 million, CEO Thomas Miller) is a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform 🇬🇧 Autolus Therapeutics (Feb 2024, equity investment, $250 million $350 million, CEO Christian Itin) is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies 🇮🇳 Global Dental Services (Nov 2023, equity investment, $50 million, CEO Amarinder Singh) India's largest tech-enabled-dental-platform that operates more than 400 company-owned and company-operated dental clinics under the “Clove Dental" banner 🇺🇸 BridgeBio (Sep 2023, PIPE financing, $250 million, CEO Neil Kumar) is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers 🇺🇸 Star Therapeutics (Sep 2023, Series C, $90 million, CEO Adam Rosenthal) is a biotechnology company with a mission to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need Contact QIA Healthcare Investment Team https://lnkd.in/ezbyKmtM Investment in funds: 🇶🇦🤝🇫🇷 Future French Champions (May 2024, €300 million) is a joint-venture between Qatar Investment Authority (QIA) and Bpifrance that has invested almost €600 million over two phases to boost economic growth and innovation in France. As the 3rd phase, they have announced intention to increase their commitment by up to another €300 million once the current commitment is fully deployed.  The strategic priorities:  🤖 Artificial Intelligence (AI) 🏿 Semiconductors ⚛️ Quantum Computing 🏥 Healthcare 🚀 Aerospace ⚡ Energy Transition This year, QIA also announced (https://lnkd.in/eARVkTBT) the creation of a $1 billion VC fund of funds to support the development of the local entrepreneurial ecosystem. The sectors of interest: 🖥 Technology 🏥 Healthcare 💳 Fintech 🎓 Edtech Contact QIA Funds Investment Team https://lnkd.in/eRVD5r7k 

Kyverna Therapeutics aims to be the fifth biotech to IPO in 2024 as the autoimmune CAR-T cell therapy maker sets its sights on $182 million in net proceeds from a listing as “KYTX.”... ... CG Oncology and ArriVent Biopharma kicked things off last week with upsized offerings and strong first days. Alto Neuroscience and Fractyl Health are expected to float in the coming days... ...Kyverna is one of the early movers in the autoimmune CAR-T cell therapy space... KYV-101, licensed from the The National Institutes of Health , is already in the clinic for lupus nephritis...... #autoimmunedisease #clinicaltrials #lupus #lupustherapies #earlymover #IPO #publicmarkets #financing #funding #biotech #biotechnology #pharmaceutical #pharma #lifesciences #therapeutics #cellandgenetherapy #celltherapy #advancedtherapies #regenerativemedicine #182m #funding2025 Peter Maag Vida Ventures, LLC Westlake Village BioPartners® Gilead Sciences Northpond Ventures Bain Capital RTW Investments, LP ElevateBio Oxford Biomedica #carttherapies

To read the full report, click on the link in the original post comments 

It’s so rewarding knowing that with your work, you can make a difference in the lives of people living with a rare disease. With our marketing efforts, we aim to increase awareness of the disease, improve diagnosis, and ensure patients in need have access to this first available treatment in Europe. Because every single life counts. #rewards #marketing #healthcare #rarediseases #diagnosis